|
KMID : 0104920210300020001
|
|
Journal of Hawhwa Medicine
2021 Volume.30 No. 2 p.1 ~ p.6
|
|
|
A Prolonged Drug Resistance Case of Non-Small Cell Lung Cancer Patient Treated with Samchilchoongcho-Jung in combining with Gefitinib
|
|
Ko Myung-Hyun
Ban Kyung-Tae
Park So-Jung
Park Ji-Hye
Lee Yeon-Weol
Cho Jung-Hyo
Yoo Hwa-Seung
|
|
|
Abstract
|
|
|
Objective : The purpose of this study was to report the case of prolonged drug resistance non-small cell lung cancer (NSCLC) with Samchilchoongcho-Jung (HAD-B1) in combining with Gefitinib.
Methods : The patient was diagnosed with Epidermal Growth Factor Receptor mutation (EGFR) NSCLC adenocarcinoma. The patient being treated with Gefitinib was treated with HAD-B1 for prolonged drug resistance. The clinical outcomes were measured by Response Evaluation Criteria in Solid Tumors (RECIST), National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE), laboratory findings, etc.
Results : After combining treatment, the drug resistance of Gefitinib was prolonged about 20 months. The tumor marker levels were also maintained. NCI-CTCAE 6.0 showed no adverse events.
Conclusion: This case study suggested that HAD-B1 may prolong the drug resistance of Gefitinib.
|
|
|
KEYWORD
|
|
|
Non-small cell lung cancer, adenocarcinoma, EGFR mutated, Herbal Medicine, Gefitinib, HAD-B1, drug resistance
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|